Trademarks = 1

Forward Citations = 19

Loading Chart...

2 inventors (with patents filed for the assignee):

Indu Muni (8 out of 20 patents)

Naomi Vishnupad (8 out of 11 patents)

8 patents: Sort by Forward Citations

1. 12514819 - Colchicine drug-to-drug interactions (2026-01-06),

2. 12409166 - Methods and compositions for oral pilocarpine liquid (2025-09-09),

3. 12274751 - Composition and method of the use of colchicine oral liquid (2025-04-14),

4. 11672759 - Colchicine drug-to-drug interactions (2023-06-13),

5. 10383821 - Colchicine drug-to-drug interactions (2019-08-20),

6. 10383820 - Colchicine drug-to-drug interactions (2019-08-20),

7. 10226423 - Colchicine drug-to-drug interactions (2019-03-12),

8. 9907751 - Composition and method of use of colchicine oral liquid (2018-03-06),

Company Overview

Rxomeg Therapeutics LLC is a biopharmaceutical company focused on developing innovative therapeutic solutions for complex and rare diseases. Our team of experts is dedicated to advancing precision medicine targeting specific genetic mutations to improve patient outcomes. With a strong commitment to research and development, we aim to bring cutting-edge treatments to market to address unmet medical needs.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

8 Patents

#71 in Woburn, MA

#2,101 in Massachusetts

#35,941 in US

Woburn, MA, United States of America

Rxomeg Therapeutics LLC

Forward Citations = 19

2 inventors:

Indu Muni (8 out of 20 patents)

Naomi Vishnupad (8 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Rxomeg Therapeutics LLC. Retrieved from https://idiyas.com/company/rxomeg-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]